(Q24245957)

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

Present situation and new strategies for Chagas disease chemotherapy: a proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

Transfusion-associated acute Chagas disease acquired in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

Chagas' disease challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

Rational modification of a candidate cancer drug for use against Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

A key role for old yellow enzyme in the metabolism of drugs by Trypanosoma cruzi

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

American trypanosomiasis (Chagas' disease) and blood banking in Mexico City: seroprevalence and its potential transfusional transmission risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

A critical review on Chagas disease chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

Ergosterol biosynthesis and drug development for Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

7 January 2021

Variance imputation for overviews of clinical trials with continuous response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

7 January 2021

Parasitic diseases of the heart I: Acute and chronic Chagas' disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

7 January 2021

The Southern Cone Initiative against Chagas disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

7 January 2021

Benznidazole and Chagas disease: can an old drug be the answer to an old problem?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

7 January 2021

Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice after late trypanomicidal treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

7 January 2021

Prevention of transfusional Trypanosoma cruzi infection in Latin America

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

7 January 2021

Parasitological cure of Chagas disease: is it possible? Is it relevant?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

7 January 2021

Chagas disease: criteria of cure and prognosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

7 January 2021

Trypanosoma cruzi infection in Triatoma infestans and other triatomines: long-term effects of a control program in rural northwestern Argentina

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

7 January 2021

Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

7 January 2021

Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

7 January 2021

Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

7 January 2021

Transfusion-associated Trypanosoma cruzi infection in a non-endemic area

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004102.PUB2

7 January 2021